Overview


According to FutureWise analysis the market for chemotherapy in 2023 is US$ 51.74 billion, and is expected to reach US$ 109.46 billion by 2031 at a CAGR of 9.80%.

Chemotherapy is an aggressive chemical medicinal treatment designed to kill the body's rapidly proliferating cells. Since cancer cells grow and divide more quickly than other cells, it is typically utilized to treat cancer. Surgery, radiation, or hormone therapy are a few examples of other treatments that are frequently used with chemotherapy. Combination therapy's utilization is influenced by a number of factors, including the cancer's stage, the patient's general health, any prior cancer treatments, and more. It is regarded as a systemic treatment that impacts the entire body. Chemotherapy has been shown to effectively combat cancer cells, but it can also have harmful side effects that can significantly lower patient's quality of life.

Chemotherapy stops tumor growth and cell division, preventing invasion and metastasis. However, because chemotherapy also impacts normal cells, this leads to hazardous side effects. Tumor growth can be slowed down at various degrees inside the cell and in its surroundings. Traditional chemotherapy drugs largely disrupt the macromolecular synthesis and function of malignant cells by interfering with the production of DNA, RNA, or proteins or impairing the proper operation of the preformed molecule. Combination chemotherapy is frequently used to get sufficient results. Traditional chemotherapy drugs largely disrupt the macromolecular synthesis and function of malignant cells by interfering with the production of DNA, RNA, or proteins or impairing the proper function of the preformed molecule. Combination chemotherapy is frequently used to achieve satisfactory outcomes. The delivery of chemotherapy is possible in neoadjuvant, adjuvant, combination, and metastatic settings. A treatment administered before the main therapy is called neoadjuvant therapy. Adjuvant therapy, which is a form of secondary treatment used in conjunction with primary therapy, has the ability to slow or stop the growth of occult cancer cells. The current standard of care for ovarian, colorectal, breast, and lung malignancies is adjuvant therapy. In malignancies including head and neck, lung, and anal, combined therapies like chemotherapy and radiation reduce the tumor before surgery or treatments with a curative purpose. Therefore, multitargeted therapy or combination therapy is more effective in most cancer treatments than single-agent therapy.

In terms of mortality, cancer is now the second leading cause of death globally, surpassing cardiovascular disorders. Environmental elements like smoking, dietary changes, urbanization, and prolonged post-reproductive lifespan are the main causes of this disease. For example, according to the World Health Organisation (WHO), there will be 29.4 million new instances of cancer worldwide by 2040, up from 18.1 million in 2018. Chemotherapy, the most popular cancer treatment, is frequently combined with other cancer drugs. Lung, breast, prostate, and colorectal cancer are the four most common kinds of cancer. Additionally, the booming biopharmaceutical industry has created several novel and ground-breaking medications that effectively target cancer cells while sparing healthy cells. The global market for chemotherapies is expanding rapidly due to the growing public knowledge of the availability of numerous advanced treatments to treat cancer. Moreover, chemotherapy has effectively extended the life of cancer patients by a few years. Infusing cancer-fighting drugs (customized nanoparticles) into sick areas without harming healthy cells is now possible thanks to a recent development in chemotherapy. This technique has been demonstrated to preserve healthy tissue while removing cancerous cells. Medical professionals can utilize photon lasers to trace the release of these nanoparticles—which have tubes and pores—into a patient's body and their length and distribution while treating cancerous cells. This method is undergoing a clinical trial at the University of California, Los Angeles. It has shown promise in the early phases of cancer patient treatment and will soon be available as chemotherapeutics. However, the high cost of chemotherapeutic treatment will constrain the market's expansion. The market for chemotherapeutic drugs will face difficulties due to a shortage of highly skilled specialists and favorable governmental healthcare systems in emerging nations. Also serving as a barrier are the negative side effects of chemotherapy medications, which include cardiac issues, low red blood cell counts, fatigue, hair loss, diarrhea, weight loss, impaired liver, kidney, and lung function, decreased bone density, and general ignorance.

FutureWise Market Research has published a report that provides an insightful analysis of chemotherapy market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, the chemotherapy market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Indication

  • Colorectal Cancer
  • Breast Cancer
  • Lung Cancer
  • Stomach Cancer
  • Ovarian Cancer
  • Lymphoma
  • Prostate Cancer
  • Leukemia
  • Others  

By Drug Class

  • Topoisomerase Inhibitors
  • Mitotic inhibitors
  • Antitumor antibiotic
  • Alkylating agents
  • Others

By Route of Administration

  • Subcutaneous
  • Intra-Muscular
  •  Intravenous
  • Intravesicular
  • Intraventricular/Intrathecal
  • Topical
  • Oral
  • Intraperitoneal
  • Others

By End User

  • Hospitals and Clinics
  • Specialty Centers
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  •  Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Chemotherapy Market By Indication, By Drug Class, By Route of Administration, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com.

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Chemotherapy Market Variables, Trends and Scope
    •        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Chemotherapy Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Chemotherapy Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Chemotherapy Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Colorectal Cancer
        2. Breast Cancer
        3. Lung Cancer
        4. Stomach Cancer
        5. Ovarian Cancer
        6. Lymphoma
        7. Prostate Cancer
        8. Leukemia
        9. Others

  • 8.   Chemotherapy Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Topoisomerase Inhibitors
        2. Mitotic inhibitors
        3. Antitumor antibiotic
        4. Alkylating agents
        5. Others

  • 9.   Chemotherapy Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Subcutaneous
        2. Intra-Muscular
        3. Intravenous
        4. Intravesicular
        5. Intraventricular/Intrathecal
        6. Topical
        7. Oral
        8. Intraperitoneal
        9. Others

  • 10.   Chemotherapy Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals and Clinics
        2. Specialty Centers
        3. others

  • 11.   North America Chemotherapy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Chemotherapy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Chemotherapy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Chemotherapy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Bristol-Myers Squibb Company
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Celgene Corporation
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Eli Lilly and Company
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. F. Hoffmann-La Roche Ltd.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. GlaxoSmithKline PLC.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Johnson and Johnson Services Inc.
                   6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
             7. Merck & Co. Inc.
                   7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
             8. Novartis AG
                   8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
             9. Pfizer Inc.
                   9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
             10. Sanofi S.A.
                   10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview          

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients